
|Articles|September 16, 2004
'PSA era is over in the United States,' leading researcher says
PSA has lost its value as a screening tool for prostate cancer and does nothing more than indicate the size of the prostate gland, according to a study led by Thomas A. Stamey, MD, and published in the October issue of the Journal of Urology (2004; 172:1297-1301).
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
4
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
5






